Overview - About ATCOR


ATCOR develops and markets medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. We help clinicians with early detection of target organ damage and management of cardiovascular and renal disease.

Our SphygmoCor® technology enables researchers and clinicians to measure noninvasive central blood pressure (NcBP), the central arterial pressure waveform, central aortic pressures, and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the SphygmoCor system, provides clinicians with better prognostic and diagnostic information to target interventions—effects which cannot be detected with standard brachial blood pressure measurement alone.

More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions, and in various clinical trials with leading pharmaceutical companies. Our technology is featured in over 4,000+ peer-reviewed publications in leading medical journals.

About CardieX


CardieX is an ASX-listed public company with a focus on medical technologies, wearable devices, and telehealth solutions. We provide digital and device-based solutions for large-scale population health disorders with significant market scale. Our fundamental mission is to develop a significant and valuable healthcare ecosystem of complementary and strategic products and services in order to provide smarter tools to help identify, diagnose, and treat patients with confidence. Our core medical business (ATCOR) develops medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. Our wearable and "smart device" division (CardieX Labs in partnership with Blümio) develops noninvasive wearable technologies that identify patient risk profiles for hypertension, CVD, and related disorders. Our telehealth group (via our investment in InHealth) develops and provides clinically based health coaching to health insurance networks, private practice, and medical device companies.